Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
35 Pulmonary Arterial Hypertension Trials
Power is an online platform that helps thousands of Pulmonary Arterial Hypertension patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerRalinepag for Pulmonary Arterial Hypertension
Oklahoma City, OklahomaThis trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Liver Disease, Renal Insufficiency, Malignancy, Others
Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors
1000 Participants Needed
Seralutinib for Pulmonary Arterial Hypertension
Oklahoma City, OklahomaThis trial is testing a medication called seralutinib to see if it can help people with a specific type of lung disease (PAH) improve their ability to exercise. The medication works by blocking signals that cause the blood vessels in the lungs to tighten and narrow. Seralutinib is delivered via inhalation and is being developed for patients with pulmonary arterial hypertension. The goal is to see if this can reduce lung pressure and delay worsening of the disease.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis, Hypertension, Others
Must Be Taking:Endothelin Antagonists, PDE5 Inhibitors
350 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Oklahoma City, OklahomaThis trial is testing sotatercept, a medication for high blood pressure in the lungs, in adults with PAH who have completed earlier studies. It aims to see if the medication is safe and effective over a long period. Sotatercept helps lung blood vessels function better, reducing lung pressure. Sotatercept has shown promising results in earlier studies for reducing lung pressure and improving exercise tolerance in patients with pulmonary arterial hypertension (PAH).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Missed Doses, Others
Must Be Taking:PAH Therapy
700 Participants Needed
High-Dose Macitentan for PAH
Oklahoma City, OklahomaThis trial is testing if a higher dose of macitentan can better help patients with pulmonary arterial hypertension by improving blood flow in their lungs. Macitentan has shown promise in helping patients by slowing down the disease and improving their health.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
935 Participants Needed
Treprostinil for Pulmonary Arterial Hypertension
Tulsa, OklahomaThe primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Amphetamine Use, Hepatic Impairment, Others
Must Be Taking:Endothelin Antagonists, PDE-5 Inhibitors
50 Participants Needed
GB002 for Pulmonary Arterial Hypertension
Oklahoma City, OklahomaThis trial will study the long-term effects of GB002 (seralutinib) in patients who were part of an earlier study for Pulmonary Arterial Hypertension (PAH). Seralutinib is a new treatment developed for PAH and has shown better results compared to another treatment in early studies.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Hypertension, Heart Disease, Infections, Others
Must Be Taking:PAH Therapies
100 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Oklahoma City, OklahomaThis trial is testing sotatercept, a new medication, to see if it can help people with a specific type of high blood pressure in the lungs (PAH) when added to their usual treatment. The study focuses on patients who are newly diagnosed and at higher risk of their condition worsening. Sotatercept aims to reduce the pressure in the lung's blood vessels, potentially slowing down disease progression. Sotatercept has shown significant reduction in pulmonary vascular resistance and maintained clinical efficacy in previous studies.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
444 Participants Needed
Ralinepag for Pulmonary Arterial Hypertension
Oklahoma City, OklahomaThis trial tests ralinepag, a medication for lung disease, on patients with PAH who participated in earlier research. It aims to improve blood flow in the lungs by relaxing blood vessels and reducing pressure.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:18 - 75
Sex:All
1000 Participants Needed
Neuromodulation for Pulmonary Arterial Hypertension
Oklahoma City, OklahomaPatients with Group 1 pulmonary hypertension will be enrolled in this study. Investigators will test the hypothesis of low-level tragal stimulation in patients with pulmonary hypertension. The study will be conducted over 4 weeks and patients will undergo low-level tragus stimulation for 1 hour every day for 4 weeks. At baseline the following tests will be conducted-6-minute walk distance, vascular function testing using noninvasive device and blood samples will be collected. Patient will also undergo a limited echocardiography to assess right ventricular function. After 4 weeks of stimulation patients will come back to undergo these tests again. Investigators hypothesized that low-level tragus stimulation (neuromodulation) will lead to improvement in vascular function, 6-minute walk distance and blood based biomarkers in patients with pulmonary hypertension.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1, 2
Age:18 - 90
Sex:All
50 Participants Needed
Seralutinib for Pulmonary Arterial Hypertension
Kansas City, KansasThis open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Medical Abnormality, Others
Must Be Taking:Seralutinib
300 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Kansas City, KansasResearchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs.
The goal of the study is to learn:
* What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial.
* About the safety of sotatercept and if people tolerate it
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Hypertension, Coronary Artery Disease, Obstructive Sleep Apnea, Others
160 Participants Needed
Treprostinil Palmitil for Pulmonary Arterial Hypertension
Kansas City, KansasThis trial is testing an inhalable medicine called TPIP to see if it can help people with high blood pressure in their lungs by making it easier for blood to flow through their lung arteries.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
102 Participants Needed
KER-012 for Pulmonary Arterial Hypertension
Kansas City, KansasThis trial is testing KER-012, a new injectable medication, in adults with a specific type of high blood pressure in the lungs. The goal is to see if it can lower lung blood pressure and help patients walk better.
Trial Details
Trial Status:Active Not Recruiting
Age:18+
Sex:All
113 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Kansas City, KansasThis trial is testing sotatercept added to current treatments for patients with severe PAH who are at high risk of death. The goal is to see if it can lower lung blood pressure and improve patient outcomes. Sotatercept, which modulates bone morphogenic protein receptor type 2 (BMPR2) signaling, showed promising results in earlier studies.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Age:18 - 75
Sex:All
172 Participants Needed
Inhaled Vardenafil for Pulmonary Arterial Hypertension
Kansas City, KansasThis trial is testing an inhaled medication called RT234. It aims to help people with pulmonary arterial hypertension (PAH) breathe better and exercise more easily. The medication works by widening the blood vessels in the lungs, making it easier for the heart to pump blood. RT234 is being developed to improve exercise tolerance and symptoms in patients with PAH.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Age:18 - 80
Sex:All
42 Participants Needed
Inhaled Treprostinil for Pulmonary Arterial Hypertension
Kansas City, KansasThe primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
92 Participants Needed
Oral Ifetroban for Scleroderma
Omaha, NebraskaThis trial is testing ifetroban, an oral medication, in patients with severe forms of systemic sclerosis. The goal is to see if it can reduce inflammation and improve blood flow, potentially helping to manage their condition better.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Lung Disease, Kidney Disease, Others
Must Be Taking:Oral PAH Therapy
34 Participants Needed
Treprostinil Palmitil for PAH
Dallas, TexasThe primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Heart Disease, Thromboembolic Disease, COVID-19, Others
Must Not Be Taking:Parenteral Prostacyclin Analogues
100 Participants Needed
The purpose of the DelIVery for PAH clinical study is to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter when used with the Medtronic SynchroMed® II Implantable Infusion System to deliver Remodulin® (treprostinil) Injection.
As of June 2021, PMA approval of the Implantable System for Remodulin (ISR) is no longer being pursued and development and commercialization efforts have been halted. The approximately 30 subjects still implanted with the PIVoT system require a pathway for continued support. This protocol is amended and is designed to allow such ongoing support.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
64 Participants Needed
Macitentan for Pulmonary Hypertension
Aurora, ColoradoThis trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:1 - 17
Sex:All
165 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Aurora, ColoradoThis trial is testing a medication called sotatercept to see if it is safe and how it acts in children with high blood pressure in the lungs, who are already on standard treatments. The study will last for several months. Sotatercept has shown promise in improving exercise tolerance in adults with pulmonary arterial hypertension.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:1 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Left-sided Heart Disease, Eisenmenger Syndrome, Pulmonary Veno-occlusive Diseases, Coronary Disease, Others
Must Be Taking:PDE5 Inhibitors, ERAs, SGCS, Prostanoids
42 Participants Needed
Selexipag for Pulmonary Arterial Hypertension
Aurora, ColoradoThis trial aims to find the right dose of Selexipag for children with Pulmonary Arterial Hypertension (PAH). Selexipag helps by relaxing lung blood vessels, lowering blood pressure, and improving blood flow. The goal is to ensure the treatment is safe and effective for younger patients.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 17
Sex:All
63 Participants Needed
Mono vs Dual Therapy for Pediatric Pulmonary Hypertension
Aurora, ColoradoThe investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:3 - 18
Sex:All
Key Eligibility Criteria
Disqualifiers:Syncope, RV Failure, Pregnancy, Others
Must Not Be Taking:Cyclosporine, Glyburide, CYP3A Inhibitors, Others
100 Participants Needed
Selexipag for Pulmonary Arterial Hypertension
Aurora, ColoradoThe purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2 - 17
Sex:All
138 Participants Needed
Sotatercept for Pulmonary Arterial Hypertension
Rochester, MinnesotaThe purpose of this study is to see if the drug sotatercept given for 36 weeks improves the functioning of the heart and improves quality of life.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Recent Heart Attack, Stroke, Anemia, Others
21 Participants Needed
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
Rochester, MinnesotaThe purpose of this research is to gather information on the safety and effectiveness of a new procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 50
Sex:Female
Key Eligibility Criteria
Disqualifiers:Multi-fetal Pregnancy, Latex Allergy, Preterm Labor, Others
10 Participants Needed
LTP001 for Pulmonary Arterial Hypertension
Austin, TexasA study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 100
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiac Abnormalities, Hypersensitivity, Others
Must Be Taking:PAH Therapies
232 Participants Needed
Exercise Training for Pulmonary Arterial Hypertension
Rochester, MinnesotaThe investigators are doing this research study to compare whole body aerobic training with isolated leg training (with weights) and its impact on effectiveness in symptoms and quality of life in patients with Pulmonary Arterial Hypertension (PAH).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Heart Failure, Anemia, Pregnancy, Others
45 Participants Needed
Aria CV System for Pulmonary Arterial Hypertension
Rochester, MinnesotaThis trial is testing a new device called the Aria CV PH System, which helps manage high blood pressure in the lungs and supports heart function. It is aimed at patients with pulmonary hypertension and related heart issues. The study will check if the device is safe and effective over a period of several months to a few years.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Renal Insufficiency, Scleroderma, Others
Must Be Taking:PH Specific Medications
30 Participants Needed
Inhaled Treprostinil for Pulmonary Hypertension
Rochester, MinnesotaThis trial is testing an inhaled medication called treprostinil on patients with a lung condition that makes it hard for them to exercise. The medication helps by improving blood flow in the lungs. Researchers want to see if it makes exercise easier and improves quality of life after a period of use. Treprostinil has been shown to improve exercise capacity and is more convenient due to its longer-lasting effects.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Age:18+
Sex:All
24 Participants Needed
Page 1 of 2+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Pulmonary Arterial Hypertension clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Pulmonary Arterial Hypertension clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Pulmonary Arterial Hypertension trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Pulmonary Arterial Hypertension is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Pulmonary Arterial Hypertension medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Pulmonary Arterial Hypertension clinical trials ?
Most recently, we added Neuromodulation for Pulmonary Arterial Hypertension, Mobile Health Intervention for Pediatric PAH and Sotatercept for Pulmonary Arterial Hypertension to the Power online platform.